Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors

Autor: Chan-Ju A. Wang, Anthony O'Grady, Nebras Al-Attar, John Crown, Seodhna M. Lynch, Joanna Fay, Fiona Lanigan, Tony Loughman, Peter Dynoodt, Katherine M. Sheehan, Darran P. O'Connor, William M. Gallagher, Bozena Fender, Desmond O'Leary, Catherine M. Kelly, Adrian P. Bracken, Arman Rahman, Stephen Barron, Rut Klinger, Niamh Russell, Verena Amberger-Murphy, Claudia Aura Gonzalez, Anurati Saha, Cesar Lopez-Ruiz
Rok vydání: 2021
Předmět:
0301 basic medicine
Oncology
Adult
Cancer Research
medicine.medical_specialty
Antineoplastic Agents
Hormonal
Receptor
ErbB-2
Risk management tools
Breast Neoplasms
Kaplan-Meier Estimate
Risk Assessment
Disease-Free Survival
03 medical and health sciences
Young Adult
0302 clinical medicine
Breast cancer
Internal medicine
medicine
Biomarkers
Tumor
Humans
Breast
Genetic Testing
Prospective Studies
Stage (cooking)
Aged
Framingham Risk Score
medicine.diagnostic_test
business.industry
Proportional hazards model
Gene Expression Profiling
Reproducibility of Results
Middle Aged
medicine.disease
Prognosis
Test (assessment)
Observational Studies as Topic
030104 developmental biology
Receptors
Estrogen
030220 oncology & carcinogenesis
Nottingham Prognostic Index
Female
Neoplasm Recurrence
Local
business
Oncotype DX
Receptors
Progesterone
Zdroj: European journal of cancer (Oxford, England : 1990). 152
ISSN: 1879-0852
Popis: The aim of the study was to assess the prognostic performance of a 6-gene molecular score (OncoMasTR Molecular Score [OMm]) and a composite risk score (OncoMasTR Risk Score [OM]) and to conduct a within-patient comparison against four routinely used molecular and clinicopathological risk assessment tools: Oncotype DX Recurrence Score, Ki67, Nottingham Prognostic Index and Clinical Risk Category, based on the modified Adjuvant! Online definition and three risk factors: patient age, tumour size and grade.Biospecimens and clinicopathological information for 404 Irish women also previously enrolled in the Trial Assigning Individualized Options for Treatment [Rx] were provided by 11 participating hospitals, as the primary objective of an independent translational study. Gene expression measured via RT-qPCR was used to calculate OMm and OM. The prognostic value for distant recurrence-free survival (DRFS) and invasive disease-free survival (IDFS) was assessed using Cox proportional hazards models and Kaplan-Meier analysis. All statistical tests were two-sided ones.OMm and OM (both with likelihood ratio statistic [LRS] P 0.001; C indexes = 0.84 and 0.85, respectively) were more prognostic for DRFS and provided significant additional prognostic information to all other assessment tools/factors assessed (all LRS P ≤ 0.002). In addition, the OM correctly classified more patients with distant recurrences (DRs) into the high-risk category than other risk classification tools. Similar results were observed for IDFS.Both OncoMasTR scores were significantly prognostic for DRFS and IDFS and provided additional prognostic information to the molecular and clinicopathological risk factors/tools assessed. OM was also the most accurate risk classification tool for identifying DR. A concise 6-gene signature with superior risk stratification was shown to increase prognosis reliability, which may help clinicians optimise treatment decisions.
Databáze: OpenAIRE
Externí odkaz: